scholarly journals Liver-Targeting and pH-Sensitive Sulfated Hyaluronic Acid Mixed Micelles for Hepatoma Therapy

2019 ◽  
Vol Volume 14 ◽  
pp. 9437-9452 ◽  
Author(s):  
Zhi-peng Li ◽  
Gui-xiang Tian ◽  
Hong Jiang ◽  
Rui-yan Pan ◽  
Bo Lian ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Mixed Micelles ◽  
Ph Sensitive ◽  
Liver Targeting

Harmine-loaded galactosylated pluronic F68-gelucire 44/14 mixed micelles for liver targeting

2019 ◽  
Vol 45 (8) ◽  
pp. 1361-1368 ◽  
Author(s):  
Jeetendra Prasad Kushwaha ◽  
Debjani Baidya ◽  
Sharvil Patil
Keyword(s):  
Mixed Micelles ◽  
Pluronic F68 ◽  
Liver Targeting

scholarly journals Tumor-Homing pH-Sensitive Extracellular Vesicles for Targeting Heterogeneous Tumors

Pharmaceutics ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 372 ◽  
Author(s):  
Jaeduk Park ◽  
Hyuk Lee ◽  
Yu Seok Youn ◽  
Kyung Taek Oh ◽  
Eun Seong Lee
Keyword(s):  
Hyaluronic Acid ◽  
Tumor Cells ◽  
Extracellular Vesicles ◽  
Cellular Uptake ◽  
Deoxycholic Acid ◽  
Ph Sensitive ◽  
Acidic Ph ◽  
Cell Cytotoxicity ◽  
Tumor Treatment ◽  
Tumor Homing

In this study, we fabricated tumor-homing pH-sensitive extracellular vesicles for efficient tumor treatment. These vesicles were prepared using extracellular vesicles (EVs; BTEVs extracted from BT-474 tumor cells or SKEVs extracted from SK-N-MC tumor cells), hyaluronic acid grafted with 3-(diethylamino)propylamine (HDEA), and doxorubicin (DOX, as a model antitumor drug). Consequently, HDEA/DOX anchored EVs (HDEA@EVs) can interact with origin tumor cells owing to EVs’ homing ability to origin cells. Therefore, EV blends of HDEA@BTEVs and HDEA@SKEVs demonstrate highly increased cellular uptake in both BT-474 and SK-N-MC cells: HDEA@BTEVs for BT-474 tumor cells and HDEA@SKEVs for SK-N-MC tumor cells. Furthermore, the hydrophobic HDEA present in HDEA@EVs at pH 7.4 can switch to hydrophilic HDEA at pH 6.5 as a result of acidic pH-induced protonation of 3-(diethylamino)propylamine (DEAP) moieties, resulting in an acidic pH-activated EVs’ disruption, accelerated release of encapsulated DOX molecules, and highly increased cell cytotoxicity. However, EV blends containing pH-insensitive HA grafted with deoxycholic acid (HDOC) (HDOC@BTEVs and HDOC@SKEVs) showed less cell cytotoxicity for both BT-474 and SK-N-MC tumor cells, because they did not act on EVs’ disruption and the resulting DOX release. Consequently, the use of these tumor-homing pH-sensitive EV blends may result in effective targeted therapies for various tumor cells.

scholarly journals pH-Responsive Hyaluronic Acid-Based Mixed Micelles for the Hepatoma-Targeting Delivery of Doxorubicin

2016 ◽  
Vol 17 (4) ◽  
pp. 364 ◽  
Author(s):  
Jing-Liang Wu ◽  
Gui-Xiang Tian ◽  
Wen-Jing Yu ◽  
Guang-Tao Jia ◽  
Tong-Yi Sun ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Mixed Micelles ◽  
Ph Responsive ◽  
Targeting Delivery

scholarly journals Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA

2021 ◽  
Vol 22 (3) ◽  
Author(s):  
Xixi Hu ◽  
Jun Zhang ◽  
Lulu Deng ◽  
Hao Hu ◽  
Junjie Hu ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Tumor Cells ◽  
Hepatoma Cell ◽  
Ph Sensitive ◽  
Tanshinone Iia ◽  
Ovarian Cancer Cells ◽  
Ionic Surfactant ◽  
Liver Targeting ◽  
Targeting Ability

AbstractIncreasing the drug tumor-specific accumulation and controlling their release is considered one of the most effective ways to increase the efficacy of drugs. Here, we developed a vesicle system that can target hepatoma and release drugs rapidly within tumor cells. This non-ionic surfactant vesicle is biodegradable. Galactosylated stearate has been used to glycosylate the vesicles to achieve liver targeting; replacement of a portion (Chol:CHEMS = 1:1) of cholesterol by cholesteryl hemisuccinate (CHEMS) allows for a rapid release of drugs in an acidic environment. In vitro release experiments confirmed that galactose-modified pH-sensitive niosomes loaded with tanshinone IIA had excellent drug release performance in acid medium. In vitro experiments using ovarian cancer cells (A2780), colon cancer cells (HCT8), and hepatoma cell (Huh7, HepG2) confirmed that the preparation had specific targeting ability to hepatoma cells compared with free drugs, and this ability was dependent on the galactose content. Furthermore, the preparation also had a more substantial inhibitory effect on tumor cells, and subsequent apoptosis assays and cell cycle analyses further confirmed its enhanced anti-tumor effect. Results of pharmacokinetic experiments confirmed that the vesicle system could significantly extend the blood circulation time of tanshinone IIA, and the larger area under the curve indicated that the preparation had a better drug effect. Thus, the results of biodistribution experiments confirmed the in vivo liver targeting ability of this preparation. Niosomes designed in this manner are expected to be a safe and effective drug delivery system for liver cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document